Skip to content
Preprint via OpenAlex

Faculty Opinions recommendation of Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.

David Gems

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · 2009

Abstract

Inhibition of the TOR signalling pathway by genetic or pharmacological intervention extends lifespan in invertebrates, including yeast, nematodes and fruitflies; however, whether inhibition of mTOR(definition) signalling can extend lifespan in a mammalian species was unknown. Here we report that rapamycin(definition), an inhibitor of the mTOR pathway, extends median and maximal lifespan of both male and female mice when fed beginning at 600 days of age. On the basis of age at 90% mortality, rapamycin led to an increase of 14% for females and 9% for males. The effect was seen at three independent test sites in genetically heterogeneous mice, chosen to avoid genotype-specific effects on disease susceptibility. Disease patterns of rapamycin-treated mice did not differ from those of control mice. In a separate study, rapamycin fed to mice beginning at 270 days of age also increased survival in both males and females, based on an interim analysis conducted near the median survival point. Rapamycin may extend lifespan by postponing death from cancer, by retarding mechanisms of ageing, or both. To our knowledge, these are the first results to demonstrate a role for mTOR signalling in the regulation of mammalian lifespan, as well as pharmacological extension of lifespan in both genders. These findings have implications for further development of interventions targeting mTOR for the treatment and prevention of age-related diseases. PMID: 19587680 Funding information This work was supported by: NIA NIH HHS, United States Grant ID: AG022308 NIA NIH HHS, United States Grant ID: P30 AG013319-149002 NIA NIH HHS, United States Grant ID: U01 AG022307-01 NIA NIH HHS, United States Grant ID: P30 AG025707 NIA NIH HHS, United States Grant ID: P30 AG013319-139002 NIA NIH HHS, United States Grant ID: U01 AG022307-05 NIA NIH HHS, United States Grant ID: P30 AG013319 NIA NIH HHS, United States Grant ID: U01 AG022303 NIA NIH HHS, United States Grant ID: U01 AG022307 NIA NIH HHS, United States Grant ID: P30 AG013319-119002 NIA NIH HHS, United States Grant ID: U01 AG022307-05S1 NIA NIH HHS, United States Grant ID: AG022303 NIA NIH HHS, United States Grant ID: U01 AG022308 NIA NIH HHS, United States Grant ID: P30 AG013319-129002 NIA NIH HHS, United States Grant ID: U01 AG022307-03 NIA NIH HHS, United States Grant ID: U01 AG022307-04 NIA NIH HHS, United States Grant ID: P30 AG028740 NIA NIH HHS, United States Grant ID: U01 AG022307-02 NIA NIH HHS, United States Grant ID: AG13319 NIA NIH HHS, United States Grant ID: AG025707 NIA NIH HHS, United States Grant ID: AG022307 More Less keyboard_arrow_down

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.3410/f.1163081.623737
Canonical
link ↗
Fetched
2026-10-29 MST

Cite this

APA
Gems, D. (2009). Faculty Opinions recommendation of Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. <em>Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature</em>. https://doi.org/10.3410/f.1163081.623737
Vancouver
Gems D. Faculty Opinions recommendation of Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature. 2009. doi:10.3410/f.1163081.623737.
BibTeX
@unpublished{david2009Facult, title = {Faculty Opinions recommendation of Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.}, author = {David Gems}, journal = {Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature}, year = {2009}, doi = {10.3410/f.1163081.623737}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings